Brief: Alkermes Announces Commercial Availability Of Lybalvi®
18/10/2021 12:54
Oct 18 (Reuters) - Alkermes Plc ALKS.O :
* ALKERMES ANNOUNCES COMMERCIAL AVAILABILITY OF LYBALVI® FOR
THE
TREATMENT OF SCHIZOPHRENIA AND BIPOLAR I DISORDER
Source text for Eikon: ID:nPn8RbL4Ga
Further company coverage: ALKS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkermes
See all newsBrief: Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 2 At Sleep 2026
Brief: Alkermes Announces Positive Topline Results From Revitalyz Phase 3 Study Evaluating Lumryz
Brief: Alkermes Announces Effectiveness Of Mural Oncology Form 10 Registration Statement
Alkermes Plc reports results for the quarter ended in September - Earnings Summary
Brief: Alkermes Q3 Net Income USD 47.8 Million